Payment overview · 2025
General Payments
$526.19
35 reported records · 5 companies
Healthcare provider profile · identity verified
Libby A Lake, MD
Allopathic & Osteopathic Physicians|Family Medicine · GREAT FALLS, MT · NPI 1932194750
Verified facts
What the public records show
CMS Open Payments records show Libby A Lake, MD received $526.19 in general payments during 2025 across 35 reported records.
ABBVIE INC. accounted for 52.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Myrbetriq by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $275.28 | 52.3% | 17 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $154.84 | 29.4% | 13 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $44.53 | 8.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.11 | 7.0% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $14.43 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $526.19 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $163.06 | 13 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $112.22 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $112.22 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $101.87 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $52.97 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $52.97 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $44.53 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.11 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $37.11 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $14.43 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $11.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
178 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 876 | 175 |
| Atorvastatin Calcium | Atorvastatin Calcium | 642 | 151 |
| Losartan Potassium | Losartan Potassium | 608 | 148 |
| Omeprazole | Omeprazole | 555 | 126 |
| Lisinopril | Lisinopril | 502 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 459 | 98 |
| Metformin Hcl | Metformin Hcl | 422 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 400 | 95 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 367 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 352 | 50 |
| Famotidine | Famotidine | 321 | 61 |
| Simvastatin | Simvastatin | 313 | 78 |
| Gabapentin | Gabapentin | 282 | 49 |
| Montelukast Sodium | Montelukast Sodium | 282 | 62 |
| Potassium Chloride | Potassium Chloride | 273 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 270 | 50 |
| Furosemide | Furosemide | 263 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 248 | 59 |
| Tramadol Hcl | Tramadol Hcl | 229 | 55 |
| Alendronate Sodium | Alendronate Sodium | 218 | 43 |
| Meloxicam | Meloxicam | 203 | 57 |
| Sertraline Hcl | Sertraline Hcl | 196 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 190 | 43 |
| Trazodone Hcl | Trazodone Hcl | 179 | 35 |
| Eliquis | Apixaban | 178 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 171 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 161 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 158 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 152 | 50 |
| Lorazepam | Lorazepam | 151 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 147 | 31 |
| Pregabalin | Pregabalin | 143 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 136 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 37 |
| Januvia | Sitagliptin Phosphate | 135 | 15 |
| Clonazepam | Clonazepam | 133 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 133 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 129 | 33 |
| Metformin Hcl Er | Metformin Hcl | 121 | 24 |
| Bupropion Xl | Bupropion Hcl | 120 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 114 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 113 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 112 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 112 | 22 |
| Sucralfate | Sucralfate | 110 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 105 | 42 |
| Oxybutynin Chloride | Oxybutynin Chloride | 103 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 97 | 25 |
| Memantine Hcl | Memantine Hcl | 96 | 16 |
| Carvedilol | Carvedilol | 94 | 17 |
| Donepezil Hcl | Donepezil Hcl | 94 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 93 | 15 |
| Valsartan | Valsartan | 90 | 20 |
| Jardiance | Empagliflozin | 88 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 85 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 85 | 23 |
| Spironolactone | Spironolactone | 85 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 84 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 81 | 16 |
| Mirtazapine | Mirtazapine | 80 | 19 |
| Morphine Sulfate Er | Morphine Sulfate | 78 | suppressed |
| Ozempic | Semaglutide | 78 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 77 | 44 |
| Allopurinol | Allopurinol | 73 | 21 |
| Ipratropium Bromide | Ipratropium Bromide | 73 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 16 |
| Celecoxib | Celecoxib | 71 | 17 |
| Glimepiride | Glimepiride | 71 | 15 |
| Propranolol Hcl | Propranolol Hcl | 71 | 20 |
| Valacyclovir | Valacyclovir Hcl | 71 | 19 |
| Cephalexin | Cephalexin | 69 | 37 |
| Ezetimibe | Ezetimibe | 69 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 67 | 13 |
| Diazepam | Diazepam | 66 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 65 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 64 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 58 | 13 |
| Aripiprazole | Aripiprazole | 56 | suppressed |
| Ibuprofen | Ibuprofen | 56 | 11 |
| Myrbetriq | Mirabegron | 55 | suppressed |
| Prednisone | Prednisone | 54 | 39 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | suppressed |
| Calcitriol | Calcitriol | 49 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 46 | suppressed |
| Ondansetron Odt | Ondansetron | 46 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | suppressed |
| Methimazole | Methimazole | 44 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 43 | 14 |
| Dexlansoprazole Dr | Dexlansoprazole | 43 | suppressed |
| Estradiol | Estradiol | 43 | 14 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Chlorthalidone | Chlorthalidone | 41 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Lamotrigine | Lamotrigine | 36 | suppressed |
| Nystatin | Nystatin | 36 | 21 |
| Divalproex Sodium | Divalproex Sodium | 35 | suppressed |
| Verapamil Er | Verapamil Hcl | 35 | suppressed |
| Alprazolam | Alprazolam | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Fluconazole | Fluconazole | 34 | 18 |
| Linzess | Linaclotide | 34 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 30 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Ramipril | Ramipril | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 28 | 16 |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 12 |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 13 |
| Methylphenidate Hcl | Methylphenidate Hcl | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Felodipine Er | Felodipine | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 17 |
| Armour Thyroid | Thyroid,pork | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Modafinil | Modafinil | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Etodolac | Etodolac | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Azathioprine | Azathioprine | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ursodiol | Ursodiol | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Xtampza Er | Oxycodone Myristate | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Budesonide Dr | Budesonide | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Concerta | Methylphenidate Hcl | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Alosetron Hcl | Alosetron Hcl | 11 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
| Testosterone | Testosterone | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $526.19 · 35 records | ABBVIE INC. | EVENITY, Korlym, NURTEC ODT, OTEZLA, PROLIA, QULIPTA, REPATHA, UBRELVY, VRAYLAR, Veozah, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error